help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Endocrinology, doi:10.1210/en.2005-1293
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
147/3/1203    most recent
Author Manuscript (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Acconcia, F.
Right arrow Articles by Kumar, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Acconcia, F.
Right arrow Articles by Kumar, R.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*TAMOXIFEN
Endocrinology Vol. 147, No. 3 1203-1212
Copyright © 2006 by The Endocrine Society

Estrogen and Tamoxifen Induce Cytoskeletal Remodeling and Migration in Endometrial Cancer Cells

Filippo Acconcia1, Christopher J. Barnes1 and Rakesh Kumar

Department of Molecular and Cellular Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030

Address all correspondence and requests for reprints to: Dr. Rakesh Kumar, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030. E-mail: rkumar{at}mdanderson.org.

Much research effort has been directed toward understanding how estrogen [17ß-estradiol (E2)] regulates cell proliferation and motility through the rapid, direct activation of cytoplasmic signaling cascades (i.e. nongenomic signaling). Cell migration is critical to cancer cell invasion and metastasis and involves dynamic filamentous actin cytoskeletal remodeling and disassembly of focal adhesion sites. Although estrogen is recognized to induce cell migration in some model systems, very little information is available regarding the underlying pathways and potential influence of selective estrogen receptor modulators such as 4-hydroxytamoxifen on these processes. Using the human endometrial cancer cell lines Hec 1A and Hec 1B as model systems, we have investigated the effects of E2 and Tam on endometrial nongenomic signaling, cytoskeletal remodeling, and cell motility. Results indicate that both E2 and Tam triggered rapid activation of ERK1/2, c-Src, and focal adhesion kinase signaling pathways and filamentous actin cytoskeletal changes. These changes included dissolution of stress fibers, dynamic actin accumulation at the cell periphery, and formation of lamellipodia, filopodia, and membrane spikes. Longer treatments with either agent induced cell migration in wound healing and Boyden chamber assays. Agent-induced cytoskeletal remodeling and cell migration were blocked by a Src inhibitor. These findings define cytoskeletal remodeling and cell migration as processes regulated by E2 and 4-hydroxytamoxifen nongenomic signaling in endometrial cancer. This new information may serve as the foundation for the development of new clinical therapeutic strategies.




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
C. J. Barnes, K. Ohshiro, S. K. Rayala, A. K. El-Naggar, and R. Kumar
Insulin-like Growth Factor Receptor as a Therapeutic Target in Head and Neck Cancer
Clin. Cancer Res., July 15, 2007; 13(14): 4291 - 4299.
[Abstract] [Full Text] [PDF]


Home page
Mol Hum ReprodHome page
D. Gentilini, M. Busacca, S. Di Francesco, M. Vignali, P. Vigano, and A.M. Di Blasio
PI3K/Akt And ERK1/2 signalling pathways are involved in endometrial cell migration induced by 17{beta}-estradiol and growth factors
Mol. Hum. Reprod., May 1, 2007; 13(5): 317 - 322.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
M. H. Herynk, A. R. Beyer, Y. Cui, H. Weiss, E. Anderson, T. P. Green, and S. A.W. Fuqua
Cooperative action of tamoxifen and c-Src inhibition in preventing the growth of estrogen receptor-positive human breast cancer cells
Mol. Cancer Ther., December 1, 2006; 5(12): 3023 - 3031.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
F. Acconcia, B. Manavathi, J. Mascarenhas, A. H. Talukder, G. Mills, and R. Kumar
An Inherent Role of Integrin-Linked Kinase-Estrogen Receptor {alpha} Interaction in Cell Migration.
Cancer Res., November 15, 2006; 66(22): 11030 - 11038.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
B. Manavathi, F. Acconcia, S. K. Rayala, and R. Kumar
An inherent role of microtubule network in the action of nuclear receptor
PNAS, October 24, 2006; 103(43): 15981 - 15986.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
K. Ohshiro, S. K. Rayala, M. D. Williams, R. Kumar, and A. K. El-Naggar
Biological Role of Estrogen Receptor {beta} in Salivary Gland Adenocarcinoma Cells.
Clin. Cancer Res., October 15, 2006; 12(20): 5994 - 5999.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2006 by The Endocrine Society